GSK Says Shingrix Shortage, Oncology Push Continues

GlaxoSmithKline Q3 Update Notes PARP Promise, Shingrix Demand

GlaxoSmithKline said its increasingly streamlined operations are on a growth trajectory, but that capacity constraints mean demand for its popular shingles vaccine will keep outstripping supply.

gsk
GSK’s Strong Q3 Update Beat Market Forecasts • Source: Shutterstock

GlaxoSmithKline PLC beat forecasts with better-than-expected third-quarter results 30 October, as robust sales of its shingles vaccine Shingrix, its HIV franchise, and some older drugs allowed the UK’s biggest drug maker to increase its 2019 profit forecast for the second time this year.

GSK now expects 2019 Adjusted EPS (earnings per share) to be roughly flat when measured in constant exchange rates (CER)....

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Business

More from Scrip